| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.9 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | 0.0039 | 1 |